Altogen Biosystem
Altogen Biosystems is a biotechnology company dedicated to developing and manufacturing cell type-specific transfection reagents and tissue-targeted delivery systems for in vitro and in vivo applications. They focus on efficient biomolecule delivery, including DNA, RNA, siRNA, and proteins, with a broad product range for research and preclinical studies. Their mission is to enable advanced gene delivery solutions to support life sciences research, drug development, and therapeutic applications.
Industries
Nr. of Employees
medium (51-250)
Altogen Biosystem
Products
Cell-type–specific in vitro transfection kits
Transfection kits and reagent formulations optimized for many individual cell lines and primary cell types, validated for DNA, siRNA, mRNA and small protein delivery.
In vivo tissue-targeted transfection kits
Kits and reagents for systemic or local delivery in rodent models using lipid-, polymer- and nanoparticle-based carriers designed to achieve organ-preferential biodistribution.
Reagents optimized for primary and hard-to-transfect cells
Chemical transfection formulations validated for primary cultures and refractory suspension or immune cell types to improve transient and stable transfection outcomes with reduced cytotoxicity.
Electroporation kits and optimized buffers
Consumable kits and buffer formulations for electroporation workflows, matched to specific cell types to improve viability and delivery efficiency.
Transfection control reagents
Positive and negative control plasmids and non-targeting/functional control siRNAs for assay benchmarking and validation of transfection workflows.
Cell-type–specific in vitro transfection kits
Transfection kits and reagent formulations optimized for many individual cell lines and primary cell types, validated for DNA, siRNA, mRNA and small protein delivery.
In vivo tissue-targeted transfection kits
Kits and reagents for systemic or local delivery in rodent models using lipid-, polymer- and nanoparticle-based carriers designed to achieve organ-preferential biodistribution.
Reagents optimized for primary and hard-to-transfect cells
Chemical transfection formulations validated for primary cultures and refractory suspension or immune cell types to improve transient and stable transfection outcomes with reduced cytotoxicity.
Electroporation kits and optimized buffers
Consumable kits and buffer formulations for electroporation workflows, matched to specific cell types to improve viability and delivery efficiency.
Transfection control reagents
Positive and negative control plasmids and non-targeting/functional control siRNAs for assay benchmarking and validation of transfection workflows.
Services
GLP-capable nonclinical studies including xenograft efficacy models, pharmacology/toxicology testing, biodistribution and IND-enabling research.
Turnkey production of stably expressing cell lines using antibiotic-selection workflows, kill-curve determination and clone expansion.
Design and synthesis of siRNA/miRNA, encapsulation into delivery carriers, quantitative measurement of mRNA/protein knockdown, and in vivo tissue-targeting validation.
Development and validation of ELISA, enzymatic assays, qPCR, Western blot and immunohistochemistry for research and GLP contexts.
Standardized cell proliferation and cytotoxicity assays, IC50 determinations and flow cytometry-based endpoints across broad cell panels.
Custom formulation and encapsulation of nucleic acids and proteins into liposomes, PEGylated liposomes, polymers or nanoparticle carriers for in vitro and in vivo delivery.
GLP-capable nonclinical studies including xenograft efficacy models, pharmacology/toxicology testing, biodistribution and IND-enabling research.
Turnkey production of stably expressing cell lines using antibiotic-selection workflows, kill-curve determination and clone expansion.
Design and synthesis of siRNA/miRNA, encapsulation into delivery carriers, quantitative measurement of mRNA/protein knockdown, and in vivo tissue-targeting validation.
Development and validation of ELISA, enzymatic assays, qPCR, Western blot and immunohistochemistry for research and GLP contexts.
Standardized cell proliferation and cytotoxicity assays, IC50 determinations and flow cytometry-based endpoints across broad cell panels.
Custom formulation and encapsulation of nucleic acids and proteins into liposomes, PEGylated liposomes, polymers or nanoparticle carriers for in vitro and in vivo delivery.
Expertise Areas
- Non-viral delivery formulation and encapsulation
- Preclinical in vivo tissue-targeted delivery for rodent models
- Cell-type–specific in vitro transfection and protocol optimization
- Stable cell line generation and clone selection
Key Technologies
- Lipid- and PEGylated liposome-based delivery
- Polymer- and nanoparticle-based delivery platforms
- Electroporation and physical transfection methods
- High-throughput reverse-transfection (96/384/1536 formats)
News & Updates
Altogen Biosystems announced the launch of a new lungs-targeted in vivo transfection reagent for treating lung diseases.
Altogen’s nanoparticle-based in vivo transfection reagent was shown to be effective for glioblastoma-targeted delivery of plasmid DNA and siRNA.
Altogen recommends high-purity transfection reagents for delivering CRISPR/Cas9 protein complexes into cells for genome editing.
Altogen’s nanoparticle transfection reagent has been used in over 30 research publications demonstrating high efficiency.
Altogen Biosystems announced the launch of a new lungs-targeted in vivo transfection reagent for treating lung diseases.
Altogen’s nanoparticle-based in vivo transfection reagent was shown to be effective for glioblastoma-targeted delivery of plasmid DNA and siRNA.
Altogen recommends high-purity transfection reagents for delivering CRISPR/Cas9 protein complexes into cells for genome editing.
Altogen’s nanoparticle transfection reagent has been used in over 30 research publications demonstrating high efficiency.